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Recombinant A-B+ Vibrio cholerae 01 strain CVD 103-HgR is a safe, highly immunogenic,
single-dose live oral vaccine in adults in industrialized countries, Safety, excretion, immunogenic-
ity, vaccine transmissibility, and environmental introduction ofCVD 103-HgR were investigated
among 24- to 59-month-old children in Jakarta. In 81 households, I child was randomly allo-
cated a single dose of vaccine (5 X 109 cfu) and another, placebo. Additionally, 139 unpaired
children were randomly allocated vaccine or placebo. During 9 days of follow-up, diarrhea or
vomiting did not occur more often among vaccinees than controls. Vaccine was minimally ex-
creted and was isolated from no controls and from I (0.6%) of 177 unvaccinated family contacts.
A 4-fold or higher rise in serum vibriocidal antibody was observed in 75% ofvaccinees (IO-fold
rise in geometric mean titer over baseline). Of 135 paired placebo recipients or household con-
tacts, 5 had vibriocidal seroconversions. Moore swabs placed in sewers and latrines near 97
households failed to detect vaccine. These observations pave the way for a large-scale field trial of
efficacy.
The return of cholera to South America in explosive epi-
demic form in 1991, after a century of absence [I], has fo-
cused attention on the lack ofa satisfactory cholera vaccine.
The venerable inactivated whole cell parenteral vaccine
confers only limited (-- 50%) protection for a short time (gen-
erally 4-6 months) [2, 3]. Consequently, public health au-
thorities advise that the parenteral vaccine should play no
role in the control of epidemic or endemic cholera [4, 5]. In
contrast, the World Health Organization has targeted the
development of a new, improved cholera vaccine as a high
priority [6, 7]. To be a practical public health tool, a new
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cholera vaccine should be oral, single-dose, safe, and highly
efficacious (even in young children) [8]. Moreover, ideally,
protective efficacy should commence within a few days of
administration and should persist long-term (at least 5
years).
Oral vaccines consisting of inactivated vibrios given with
or without B subunit of cholera toxin conferred moderate
(50%-52%) protection against cholera for 3 years in a field
trial in Bangladesh [9, 10]. While constituting an advance
over the parenteral inactivated vaccine, the two oral inacti-
vated vaccines tested in Bangladesh suffer from some nota-
ble drawbacks: Young children derived only short-term pro-
tection lasting < I year [10]; protection in adults did not
persist beyond 3 years; multiple (three, perhaps as few as
two) spaced doses were necessary to confer protection [9,
10]; and protection was lower in persons of blood group 0
(an important host risk factor for cholera gravis) and against
El Tor rather than classical biotype infection.
It is anticipated that genetically engineered strains of Vib-
rio cholerae 0 I used as live oral vaccines may overcome the
drawbacks of earlier generations of cholera vaccines and
may, with a single dose, provide a high level of long-term
protection among all age groups, without causing adverse
reactions [8, 11-13]. However, the use of recombinant live
vaccines raises certain other questions that must be an-
swered, such as to what extent such strains are excreted,
whether the vaccine strain is readily transmitted to contacts,
and whether the vaccine persists in the environment.
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Strain CVD I03-HgR, presently the leading live oral chol-
era vaccine candidate, was derived from wild-type classical
V. cholerae 0 I 569B (classic biotype, Inaba serotype) using
recombinant DNA techniques [13- I5]. Ninety-four percent
of the gene encoding the A (ADP-ribosylating) subunit of
cholera enterotoxin was deleted (leaving expression of the
nontoxic B subunit intact), and a gene encoding resistance to
Hg++ was inserted into the hlyA locus of the chromosome to
provide a marker to differentiate CVD 103-HgR from wild-
type vibrios [13- 15]. The safety and immunogenicity of
CVD 103-HgR have been previously documented in ran-
domized, placebo-controlled, double-blind clinical trials and
open studies in adults in industrialized countries [14, 16- I9]
and adults and school-age children in developing countries
[20-23]. Herein we report the first clinical studies of CVD
103-HgR in preschool children in a less-developed country.
In addition to safety and immunogenicity, excretion and
transmissibility of the vaccine strain were investigated and
bacteriologic studies were done to detect the vaccine strain in
the environment around the dwellings of vaccinated sub-
jects.
Materials and Methods
Overview of the Studies
El Tor cholera occurs throughout the year in Jakarta, with
seasonal increases in June-August and in December and Jan-
uary [24, 25]. In July and August 1991, pairs ofchildren 24-59
months of age within the same household were randomly allo-
cated so that I child received, with buffer, a single dose ofCVD
103-HgR vaccine containing 5 X 109 cfu while the other re-
ceived placebo. A second round of vaccination was carried out
in January and February 1992. Because few households with
pairs of age-eligible children were available, for this round of
vaccination the protocol was modified so that (except for a small
number of household pairs) only I child 24-59 months old per
household was entered into the study and was randomly allo-
cated vaccine or placebo. Double-blind clinical surveillance de-
tected adverse reactions, and a rise in serum vibriocidal antibody
was the main outcome of immunogenicity. All participating
children and many family members had multiple stool cultures
to detect excretion of the vaccine strain. Blood specimens were
obtained from most family members who gave stool cultures. In
a proportion ofhouseholds, environmental bacteriologic studies
were carried out to detect the vaccine strain.
Study Site
The two studies were carried out in villages (kelurahans) in
North Jakarta, located within the catchment area of the In-
fectious Diseases Hospital, North Jakarta.
Subjects, Eligibility, Recruitment, and Allocation
Study 1. With active participation of the kelurahan civic
leaders, a census was undertaken to identify and describe the
study to households with 2 children 24-59 months ofage. Fami-
lies who expressed an interest in participating were invited to a
meeting where the study was again explained, questions were
answered, and the vaccination schedule was given. Interested
families who did not attend the meeting were sent an informa-
tionalletter that included vaccination date and time and a con-
sent form. For each household, one child was administered a
coded preparation labeled N and the other 0 (one signified vac-
cine and the other placebo). The older child in each pair was
inoculated first. The randomized pairs of coded preparations
and lists denoting the preparation to be administered to each
child were generated by the manufacturer. Bymaintaining bacte-
riologic and serologic surveillance ofall subjects in this random-
ized, double-blind, placebo-controlled study, it was possible to
detect evidence of transmission of the vaccine strain to placebo
recipients.
Study 2. The experience in study I and subsequent censuses
in other villages revealed that because ofsuccessful family plan-
ning programs, there were few households with pairs ofchildren
within the 24- to 59-month age group. Accordingly, the study
design was modified to include households having I child 24-59
months old. Age-eligible children were recruited as in study I.
On the day of vaccination, after a physical examination and
other measures to verify eligibility, age-eligible children from
single-subject households were randomized to receive a num-
ber-coded preparation (about one-halfofwhich corresponded to
packets ofvaccine and the remainder placebo). A separate set of
packets was available for the few pairs that were recruited for the
second study; allocation followed the procedure of the first
study except that these packets had number codes.
Vaccination was carried out in the village office near a local
health center. Children with chronic health problems, receiving
antibiotic therapy, or with acute illness on the scheduled day of
vaccination were excluded.
Vaccines and Placebo
Packets of vaccine contained 5 X 109 cfu of lyophilized, fil-
tered CVD 103-HgR [22]. Placebo (5 X 108 inactivated Esche-
richia coli K 12 organisms) was of the type extensively used in
evaluation of inactivated and live oral cholera vaccines [16, 17,
20-26]. Each packet of vaccine or placebo also contained 18.8
mg of aspartame to sweeten the vaccine cocktail and make it
more palatable to children. The sachet of buffer that accompa-
nied each packet of vaccine or placebo held 1.24 g of NaHC03
and 0.88 g ofascorbic acid. The buffer powder was stirred into a
cup containing 50 mL of nonchlorinated water, after which the
vaccine (or placebo) packet was emptied into the buffer solu-
tion, stirred again, and immediately given to the child. Parents
had been instructed that the children should refrain from eating
or drinking for I h before and after vaccination. Children were
considered vaccinated if they drank ~50% of the suspension.
Medical Supervision
Physicians visited the children daily for 9 days in their house-
holds to elicit and document complaints, do physical examina-
tions, and record axillary temperatures. The clinical follow-up,
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as well as the administration of vaccine (or placebo), was dou-
ble-blind with neither the clinical staff, the children, nor their
parents knowing the identity of the preparation given to any
child. Diarrhea was defined as passage of at least three loose
stools within 24 h. Vomiting was defined as one or more epi-
sodes of emesis. An axillary temperature ~37.5°C signified
fever. Any child who passed three or more loose stools in a 24-h
period was given oral rehydration with glucose and electrolytes.
Bacteriology
Clinical. Stool samples or rectal swabs were obtained daily
from the children on the 5 days after vaccination. During study
1, an attempt was also made to obtain stool or rectal swabs from
family members in the households as a means of monitoring for
transmission of the vaccine strain to contacts. Stool or swabs
were transported to the laboratory in Cary-Blair medium and
inoculated directly onto thiosulfate-citrate-bile salts-sucrose
(TCBS) agar or were enriched for 5-6 h in alkaline peptone
water before subculture onto TCBS agar [27]. Suspected colo-
nies were confirmed as V. cholerae by biochemical tests and as
01 serogroup by agglutination with specificantiserum. Serotyp-
ing was done by agglutination with specific Inaba and Ogawa
antisera, and preliminary biotyping was based on resistance to
polymyxin B (El Tor isolates are resistant, classical are not),
hemagglutination ofchicken erythrocytes (El Tor strains are pos-
itive), and the CAMP test (El Tor strains are positive) [28].
Environmental. Most dwellings had concrete slab latrines
that drained into open sewers. Other households had open priv-
ies. Moore swabs (4.0-cm-thick rolls ofgauze attached to nylon
string) [29, 30] were placed in open sewers (near where the
household drain entered the sewer) or privies adjacent to 27
dwellings where pairs of children were vaccinated during study
I. In study 2, Moore swabs were similarly placed near 70 addi-
tional dwellings. The Moore swabs were placed on the evening
or night of the same day as vaccination and remained in situ for
36-40 h. After retrieval, the swabs were inoculated into 250 mL
of alkaline peptone enrichment broth and incubated for 6 h at
37°C before subculture onto TCBS agar. Incubation and pro-
cessing were done in the same manner as for the stool cultures.
Serology
Venous blood (3-4 mL) was collected on the day of vaccina-
tion and 9 and 28 days thereafter. Serum Inaba vibriocidal anti-
body, the primary measurement of immune response, was as-
sayed by microtiter method [31, 32], and a fourfold or greater
rise in titer was considered significant (Le., seroconversion) [32].
Serum vibriocidal antibodies are a marker for the elicitation of
protective intestinal immune responses against V. cholerae 01
[2]. IgG cholera antitoxin was measured by ELISA in serum
specimens diluted 1:50 [33]; if the net optical density (00) of
the prevaccination specimen was ~ 1.00, sera were tested at
1:400 dilution. A ~0.20 rise in net 00 of the postvaccination
over the prevaccination specimen was considered significant
(i.e., seroconversion) [33].
Statistical Tests and Analyses
Overall rates of adverse reaction and seroconversion were
compared by x2 test with Yates's correction or by Fisher's exact
test. Adverse reaction rates and seroconversion rates among the
household pairs of children were analyzed by McNemar's
matched pairs analysis. Beforetheir analysis, serum Inaba vibrio-
cidal antibody titers were transformed to logarithms to better
approximate normality. The relationship between age of subject
and occurrence offeverwas examined by logisticregressionanal-
ysis. The relationship between age group (24-35, 36-47, and
48-59 months) and the fold rise in reciprocal geometric mean
titer (GMT) of serum Inaba vibriocidal antibody was examined
using analysis of covariance (covariate = day 0 Inaba vibriocidal
titer).
Results
Clinical tolerance. In study I, parents from 170 house-
holds with age-eligible pairs of children identified during the
census expressed interest in participating. On the day ofvac-
cination, 86 pairs of children presented, of which 80 re-
mained eligible after physical examination and age verifica-
tion and were entered into the study and vaccinated. Of the
160 children (80 pairs) who were offered vaccine or placebo
suspensions, 75 pairs ingested at least 50%of the suspension
(the cutoff for being considered vaccinated). In fact, 132
(83%) ingested the full volume. Any child from a pair who
ingested the cocktail while the sibling did not was followed
to detect adverse reactions. These surveillance data are in-
cluded in the overall analysis of reactogenicity.
In study 2, parents of 244 age-eligible children expressed
interest for their offspring to participate. On the allotted day,
185 children were brought to the vaccination site. Thirty
children were judged ineligible by the screening pediatri-
cians, leaving 155 age-eligible children who were offered
vaccine; 130 (84%) ingested the entire volume of vaccine or
placebo suspension while 149 (96%) ingested at least 50%.
In total, 81 eligible pairs of 24- to 59-month-olds were
vaccinated (75 during study 1 and 6 during study 2) and
followed for adverse reactions. Two additional children in
study 1, representing the single members within a pair who
ingested the vaccine cocktail (whereas their paired sibling
did not), were also kept under clinical surveillance. Finally,
in study 2, 139 additional children, 1 per household, re-
ceived vaccine or placebo.
The overall occurrence of diarrhea, vomiting, abdominal
cramps, and fever among these 303 recipients of vaccine or
placebo is summarized in table 1. Neither during the first 3
days of clinical follow-up (when diarrheal reactions were
most likely to occur) nor during the entire 9-day period of
follow-up were gastrointestinal adverse reactions noted sig-
nificantly more often in vaccinees. The diarrheal reactions
observed in the vaccinees and controls were mild.
Fevers were observed significantly more often in the vac-
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Table 1. Adverse reactionsamong 24- to 59-month-old Indonesian children who received a single
5 X 109 cfu dose of CVD 103-HgRor placebo, during 9 days of follow-up after immunization.
No. (%) with reaction
Abdominal
Group (n) Mean age* Diarrhea Vomiting cramps Fever
All children
Vaccinees (155) 42.5 ± 11.1 18(11.6) 16(10.3) 18(11.6) 28 (18.1)
Placebo ( 148) 44.3 ± 11.4 12 (8.1) 10(6.7) 13 (8.7) 14(9.4)
pt 0.17 0.69 0.37 0.53 0.045
Household pairs
Vaccinees (81) 41.6 ± 11.6 7(8.6) 5 (4.9) 10 (12.3) 15 (18.5)
Placebo (8 I ) 43.3 ± 11.9 4 (4.9) 4 (5.6) 7 (8.6) 10(12.3)
pt 0.93 0.53 1.00 0.30 0.55
* Months ± SD.
tUn paired I test for con tinuous data. X2 with Yates's correction (two-tailed test) for comparisons of proportions.
t Paired I test for continuous data. x2 with Yates's correction (two-tailed test) for comparisons of proportions.
cinees (18.1 %) than in the placebo recipients (8.7%; P =
.045; table I). The fevers were low-grade (the maximum tem-
perature elevation was 39.0°C in a vaccinee and 39.4°C in a
control) and clustered in the youngest children; fevers were
recorded in 29% of children 24-35 months, 16% of those
36-47 months, and 10%of those 48-59 months of age. The
relationship between age and occurrence of fever in the vac-
cine group was statistically significant (logistic regression, P
= .02). In contrast, the occurrence offever in placebo recipi-
ents was unrelated to age, being observed in 9% of children
aged 24-35 and 48-59 months and 12% of children aged
36-47 months. The fevers demonstrated a curious distribu-
tion over time. During the first 5 days of follow-up there was
no difference in the occurrence of fever: 14 (9%) of 155 vac-
cinees versus 12 (8. 1%) of 148 controls. However, during the
last 4 days of clinical follow-up, fever was observed in 14
vaccinees (9%) and only I control (0.7%; P = .002). Analysis
of the individual cases of fever that occurred among the vac-
cinees between days 6 and 9 of follow-up after vaccination
revealed that 12 of the 14 subjects had c1earcut intercurrent
infections. These included upper respiratory infections in 8
children, pharyngitis in 2, and shigellosis in I.
When the 81 pairs of24- to 59-month-olds were analyzed
separately using a matched pairs analysis, no gastrointestinal
or febrile adverse reactions were observed significantly more
frequently in vaccinees than in controls (table I).
Immunogenicily. The rate of seroconversion of serum
Inaba vibriocidal antibody among vaccinees and placebo re-
cipients for whom blood samples were available for testing is
summarized in table 2, as is the GMT before and the peak
GMT after vaccination. Overall, 75% of vaccinees mani-
fested seroconversions: the peak GMT after vaccination was
lO-fold above the baseline GMT, and 17% of children
reached reciprocal titers ~2560. Of placebo recipients, 3%
demonstrated seroconversions. The propensity to serocon-
vert was not related to age (table 2). Although the peak
GMT of vibriocidal antibody rose with age, so did the base-
line GMT, undoubtedly reflecting cumulative contact with
cholera antigens in this endemic area. The mean fold rise in
GMT was highest in the oldest stratum of children within
this cohort (analysis of covariance, P = .018; table 2). CVD
103-HgR elicited similar seroconversion rates in girls (74%)
and boys (76%).
Baseline serum antitoxin levels were exceedingly high,
with an arithmetic mean net 00 of0.92 in the vaccine group
and 0.96 in the placebo group. Despite the high baseline
titers, significant rises in serum antitoxin were observed in 31
(25%) of 125 vaccinees and in 7 (6%) of 120 placebo recipi-
ents whose sera were available for testing.
Excretion of vaccine strain by vaccinees. Of the 162 vac-
cinees from whom stool cultures were obtained, the vaccine
strain was recovered from only 4 (2.5%),2 in study I and 2 in
study 2. One child's stool cultures also yielded V. cholerae of
a serogroup other than 0 I. Wild-type V. cholerae 0 I strains
(biotype EI Tor, serotype Ogawa) were isolated from 3 vac-
cinees (I in study I and 2 in study 2).
The available classical Inaba V. cholerae 0 I isolates were
hybridized with DNA probes that detect the cholera toxin A
subunit gene and the Hg++ gene. The isolates were negative
with the former and positive with the latter probe. In con-
trast, the wild-type El Tor Ogawa isolates hybridized with the
toxin probe and were negative with the Hg++ probe.
Transmissibility of the vaccine. Transmission of the vac-
cine strain to placebo recipients and other household contact
controls was sought, directly by culturing stool to detect the
vaccine strain and indirectly by collecting blood specimens
to look for seroconversion of vibriocidal antibody. Neither
CVD 103-HgR nor wild-type El Tor V. cholerae was isolated
from stool cultures ofany ofthe 81 placebo recipients among
the household pairs. CVD 103-HgR was recovered from the
stool culture of I (0.6%) of 174 other family contacts (a
mother). Wild-type V. cholerae El Tor Ogawa was isolated
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Table 2. Serum Inaba vibriocidal antibody and serum IgG antitoxin responses following ingestionof a single 5 X 109 cfu dose of CVD
103-HgR liveoral cholera vaccine or placebo by 24- to 59-month-old Indonesian children.
Vibriocidal antibody IgG antitoxin
GMT No. (%) with Mean
Serocon version before Peak Rise titer Seroconversion before Mean
Group (n) rate* vaccinationt GMTt in GMT >2560 rate* vaccination! peak!
Vaccinees
All ages (125) 94 (75) 26 (3.2 ± 1.4) 243 (5.5 ± 1.9) 10-fold 21 (17) 31 (25) 0.92 ± 0.57 1.13 ± 0.60
24-35
months (41) 32 (78) 16 (2.8 ± 1.1) 131(4.9±1.7) 8-fold 4 (10) 8 (20) 1.10 ± 0.67 1.26 ± 0.60
36-47
months (36) 25 (69) 24 (3.2 ± 1.2) 176 (5.2 ± 1.7) 7-fold 3 (8) 9 (25) 0.95 ± 0.44 1.12 ± 0.49
48-59
months (48) 37 (77) 39 (3.7 ± 1.6) 523 (6.3 ± 1.9) 13-fold 14 (29) 14 (29) 0.75 ± 0.52 1.04 ± 0.67
Placebo,
all ages ( 120) 4 (3) 21 (3.2 ± 1.1) 23(3.1 ± 1.1) 0 7 (6) 0.95 ± 0.62 0.93 ± 0.58
* No. (%) with 4-fold or greater rises. Postvaccination blood specimens were not available from some vaccinated children.
t Reciprocal geometric mean titer (log GMT ± SO).
t Arithmetic mean net optical density units ± SO.
from another family contact (0,6%), Of the members of the
household pairs who received placebo and whose sera were
available for testing, only 1 (1.5%) of68 manifested serocon-
versions ofvibriocidal antibody; similarly, only 4 (6%) of 67
family contacts who provided serum for testing showed signif-
icant rises,
Environmental bacteriology to detect CVD l03-HgR.
Moore swabs from 26 (96%) of 27 household environments
sampled in study I yielded non-O I V. cholerae. demonstrat-
ing the sensitivity of the method. In study 2, V. cholerae of
serogroups other than 0 I were recovered from the environ-
ment (wastewater or privy) near 20 (29%) of 70 dwellings.
However, in no instance in either study did a Moore swab
culture yield the vaccine strain or V. cholerae 0 I.
Discussion
This report summarizes experiences with a single 5 X 109
cfu dose of CVD 103-HgR in 24- to 59-month-old children
living in North Jakarta. Because we were evaluating in young
children a recombinant live vaccine derived from a known
pathogenic parent strain of V. cholerae 01, we were particu-
larly concerned about the occurrence of gastrointestinal ad-
verse reactions. It is reassuring that in this randomized, pla-
cebo-controlled, double-blind study, neither diarrhea,
vomiting, nor abdominal cramps was observed significantly
more often among vaccinees. Surprisingly, febrile reactions
were noted significantly more often in vaccinees than con-
trols (18.1 % vs. 8.1%; P = ,045). These fevers, which were
mostly low-grade, clustered in the youngest children during
days 6-9 after vaccination, It is not readily apparent why an
attenuated V. cholerae 0 I vaccine would be associated with
low-grade fevers in this age group, particularly with a late
onset. In previous randomized, placebo-controlled trials in
adults and 5- to 9-year-old Indonesian children, febrile reac-
tions were not observed [14, 16-23]. Moreover, fever is not a
prominent symptom of cholera, although it has been ob-
served in 10%-20% of volunteers with experimental cholera
[34], We believe that this is a chance finding not biologically
attributable to vaccine, since careful examination ofthe clin-
ical records of each of the children who manifested fever
during the latter third of the clinical follow-up (when fever
was seen more often in vaccinees) revealed an intercurrent
infection in 12 of 14 vaccinees. The fevers in vaccinees were
not correlated with diarrhea (P = .46) or other gastrointesti-
nal adverse effects. A similarly designed reactogenicity and
immunogenicity study of CVD 103-HgR in 24- to 59-
month-olds that was recently completed in Costa Rica
showed no difference in the rate of occurrence of fever be-
tween vaccinees and controls (unpublished data).
A single dose of CVD 103-HgR was quite immunogenic.
Seventy-five percent ofvaccinees manifested significant rises
in vibriocidal antibody (the best correlate of protection) [2,
35-38], and overall the vaccinees demonstrated a mean 10-
fold rise in GMT over baseline (table 2). For the purpose of
comparison, it is of interest to note that among children 2-5
years ofage in Bangladesh who ingested three doses ofinacti-
vated whole cell V. cholerae0 1 vaccine (either alone or com-
bined with B subunit), 36% manifested 4-fold rises in serum
Inaba vibriocidal antibody and overall they exhibited a mean
4-fold increase in titer over baseline; after a single dose of
vaccine, only 18%exhibited 4-fold rises [26].
A characteristic feature ofCVD 103-HgR live oral cholera
vaccine is that while it elicits excellent immune responses, it
is minimally excreted. In these studies of those 24-59
months old, the vaccine strain was recovered from stool cul-
1174 Sirnanjuntak et al. lID 1993; 168 (November)
tures ofonly 2.5%ofvaccinees. With such minimal excretion
one would not anticipate frequent secondary transmission of
the vaccine strain. This study was designed to incorporate
conditions that would favor transmissibility: for example, the
study was carried out in 24- to 59-month-olds, an age group
in which fecal transmission occurs readily because of primi-
tive personal hygiene practices, even in industrialized set-
tings with high levels of sanitation [39, 40]; moreover,
dwellings in the study villages typically do not have piped
water or sewage disposal. Despite these conditions, neither
by stool culture nor by seroconversion of vibriocidal anti-
body was there much evidence of secondary transmission of
the vaccine strain to contacts. Since EI Tor cholera is en-
demic in North Jakarta, one cannot exclude the possibility
that some of the few seroconversions ofvibriocidal antibody
observed in placebo recipients and family contacts were due
to ingestion ofwild-type V. cholerae 0 I. Even if all the sero-
conversions among contacts were due to the live vaccine,
this would represent a secondary transmission rate of only
6% under conditions highly favorable for such transfer.
Obtaining information on transmissibility of the vaccine
strain was critical in order to design a large-scale field trial to
determine the efficacy of a single dose of CVD 103-HgR in
preventing cholera under conditions of natural challenge in
North Jakarta. Earlier field trials elsewhere that examined
the efficacy of parenteral and oral inactivated vaccines were
designed so that individual subjects were randomly allocated
to receive vaccine or placebo [41-45]. IfCVD 103-HgR live
cholera vaccine were readily transmitted to contacts, as is the
Sabin attenuated poliomyelitis vaccine [46], it would be in-
correct to design a field trial based on random allocation of
individuals. With a readily transmissible vaccine strain,
many placebo recipients inadvertently would be immunized;
as a result, the incidence of cholera in the placebo group
would be falsely low and this, in turn, would lower the calcu-
lated vaccine efficacy. Rather, to field test the efficacy of a
readily transmitted live oral cholera strain, an innovative de-
sign would be required in which the unit of random alloca-
tion would be villages or extended households, not individ-
uals. On the basis ofthe apparent low level oftransmission of
CVD 103-HgR even among preschool children, a large-
scale, randomized, placebo-controlled, double-masked field
trial, which follows the classic study design by which earlier
cholera vaccines were tested, was initiated in June 1993 in
66,000 pediatric and adult subjects in North Jakarta. This
World Health Organization-sponsored field trial will mea-
sure the efficacy of a single dose of CVD 103-HgR in pre-
venting cholera in this high-risk area.
Recombinant DNA technology has revolutionized vac-
cine development, resulting in new or improved vaccines
against many infectious diseases [47]. Nevertheless, a seg-
ment of the public and the scientific community remains
suspicious of the products of recombinant DNA technology
and of the release into the environment of genetically engi-
neered strains, including vaccines [48-52]. Although the US
Food and Drug Administration does not regulate genetically
engineered vaccines any differently than it does live vaccines
prepared by nonrecombinant means such as chemical muta-
genesis, there are advantages to using a live recombinant
vaccine such as CVD 103-HgR that is not heavily excreted
and that does not readily enter or persist in the environment.
The sensitivity and utility of Moore swab environmental
sampling to isolate Salmonella typhi [30, 53, 54] and V. cho-
ferae 0 I [29] from fecally contaminated surface waters is
well-established. Moore swabs did not recover CVD 103-
HgR from the environment around any of the 97 North Ja-
karta households sampled.
The international, multiagency Children's Vaccine Initia-
tive [55] is promulgating the concept of immunizing infants
by the oral route with single-dose, multiantigen vaccines.
The remarkable immunogenicity of a single dose of CVD
103-HgR in pediatric populations in less-developed coun-
tries [22], and its efficacy thus far in experimental challenge
studies in volunteers [14, 19], adds optimism for the generic
notion offuture multivalent single-dose oral vaccines. In this
context, CVD 103-HgR itself is being investigated as a po-
tential live vector vaccine to express foreign antigens [56].
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